Evidence map›Paper›PMID 20410132›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2010

Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury.

Shuang-Shuang Dai, Yuan-Guo Zhou, Wei Li, Jian-Hong An, Ping Li, Nan Yang, Xing-Yun Chen, Ren-Ping Xiong, Ping Liu, Yan Zhao and 3 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 157 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Adenosine APharmaceuticals (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Adenosine AJournal of neurochemistry · 2026
    Article
  7. Article
  8. Adenosine and adenosine receptors in metabolic imbalance-related neurological issues.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Review
  9. Article
  10. Targeting the adenosine AChinese journal of traumatology = Zhonghua chuang shang za zhi · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. AInternational journal of molecular sciences · 2022
    Review
  19. Review
  20. The adenosine AFrontiers in pharmacology · 2022
    Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Shuang-Shuang DaiMolecular Biology Center, State Key Laboratory of Trauma, Burn, and Combined Injury, Research Institute of Surgery and Daping Hospital, Third Military Medical University, Chongqing 400042, China.
Yuan-Guo Zhou
Wei Li
Jian-Hong An
Ping Li
Nan Yang
Xing-Yun Chen
Ren-Ping Xiong
Ping Liu
Yan Zhao
Hai-Ying Shen
Pei-Fang Zhu
Jiang-Fan Chen
Daping Hospital · CNArmy Medical University · CNBoston University · US

Funding

NOVEL BENEFIT OF A2A RECEPTOR INACTIVATION IN PD MODELSR01NS041083 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JIANG-FAN · 2001 to 2013
$3.1M
A1/A2A Receptors and Caffeine PsychostimulationR01NS048995 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHEN, JIANG-FAN · 2005 to 2009
$1.6M
NINDS NIH HHS NS41083NINDS NIH HHS NS48995NINDS NIH HHS R01 NS041083NINDS NIH HHS R01 NS048995
6 · The paper itself

Abstract

During brain injury, extracellular adenosine and glutamate levels increase rapidly and dramatically. We hypothesized that local glutamate levels in the brain dictates the adenosine-adenosine A(2A) receptor (A(2A)R) effects on neuroinflammation and brain damage outcome. Here, we showed that, in the presence of low concentrations of glutamate, the A(2A)R agonist 3-[4-[2-[[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid (CGS21680) inhibited lipopolysaccharide (LPS)-induced nitric oxide synthase (NOS) activity of cultured microglial cells, an effect that was dependent on the protein kinase A (PKA) pathway. However, in high concentrations of glutamate, CGS21680 increased LPS-induced NOS activity in a protein kinase C (PKC)-dependent manner. Thus, increasing the local level of glutamate redirects A(2A)R signaling from the PKA to the PKC pathway, resulting in a switch in A(2A)R effects from antiinflammatory to proinflammatory. In a cortical impact model of traumatic brain injury (TBI) in mice, brain water contents, behavioral deficits, and expression of tumor necrosis factor-alpha, interleukin-1 mRNAs, and inducible NOS were attenuated by administering CGS21680 at post-TBI time when brain glutamate levels were low, or by administering the A(2A)R antagonist ZM241385 [4-(2-{[5-amino-2-(2-furyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amino}ethyl)phenol] at post-TBI time when brain glutamate levels were elevated. Furthermore, pre-TBI treatment with the glutamate release inhibitor (S)-4C3HPG [(S)-4-carboxy-3-hydroxyphenylglycine] converted the debilitating effect of CGS21680 administered at post-TBI time with high glutamate level to a neuroprotective effect. This further indicates that the switch in the effect of A(2A)R activation in intact animals from antiinflammatory to proinflammatory is dependent on glutamate concentration. These findings identify a novel role for glutamate in modulation of neuroinflammation and brain injury via the adenosine-A(2A)R system.

Indexed as

AnimalsBrain InjuriesCells, CulturedGlutamic AcidInflammationInflammation MediatorsMiceMice, Inbred C57BLMice, KnockoutNeuronsReceptor, Adenosine A2AGlutamic AcidInflammation MediatorsReceptor, Adenosine A2A

Identifiers

PMID20410132
PMCPMC3842468
OpenAlexW2055976997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.